Treatment outcome and safety of anti-PD-1 antibody against elderly non-small cell lung cancer.

被引：0
|
作者：
Sakatani, Toshio
Saihara, Aya
Ikushima, Hiroaki
Takeshima, Hideyuki
Taniguchi, Yuri
Hojo, Masayuki
Usui, Kazuhiro
机构：
[1] NTT Med Ctr Tokyo, Tokyo, Japan
[2] Kanto Med Ctr NTT EC, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.e14249
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14249
引用
收藏
页数：2
相关论文
共 50 条
  • [11] Complete response with anti-PD-L1 antibody following progression on anti-PD-1 antibody in advanced non-small cell lung cancer
    Singh, Navdeep
    Seetharamu, Nagashree
    BMJ CASE REPORTS, 2020, 13 (08)
  • [12] Association Between Plasminogen Activator Inhibitor-1 & Tolerance Against Anti-PD-1 Antibody in Non-Small Cell Lung Cancer
    Sumii, M.
    Masuda, T.
    Shimoji, K.
    Yamaguchi, K.
    Sakamoto, S.
    Horimasu, Y.
    Nakashima, T.
    Iwamoto, H.
    Hamada, H.
    Hattori, N.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S156 - S157
  • [13] Predictive factors for combined anti-PD-1 and anti-angiogenic therapy in multiline treatment of advanced non-small cell lung cancer.
    Wang, Yina
    Li, Xiaobin
    Chen, Yao
    Xu, Mingyan
    Song, Lele
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [14] Clinical efficacy and safety of anti-PD-1/PD-L1 treatments in non-small cell lung cancer (NSCLC)
    Zeng, Tian
    Qin, Qin
    Bian, Zhiheng
    Li, Jianjun
    ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY, 2019, 47 (01) : 4194 - 4201
  • [15] Outcome of elderly patients with advanced non-small cell lung cancer.
    Gumus, M
    Palak, B
    Iyikesici, S
    Yumuk, PF
    Seker, M
    Topal, A
    Dane, F
    Salepci, T
    Yayla, A
    Turhal, NS
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 706S - 706S
  • [16] Retreatment With Anti-PD-L1 Antibody in Advanced Non-small Cell Lung Cancer Previously Treated With Anti-PD-1 Antibodies
    Fujita, Kohei
    Uchida, Naohiro
    Yamamoto, Yuki
    Kanai, Osamu
    Okamura, Misato
    Nakatani, Koichi
    Sawai, Satoru
    Mio, Tadashi
    ANTICANCER RESEARCH, 2019, 39 (07) : 3917 - 3921
  • [17] Serum biomarkers during the first cycle of anti-PD-1 antibody therapies in non-small cell lung cancer
    Ota, T.
    Takeda, T.
    Fukui, T.
    Nakahara, Y.
    Kudo, K.
    Okabe, T.
    Hayashi, H.
    Otani, S.
    Hiyoshi, Y.
    Yonesaka, K.
    Sugiura, T.
    Suzumura, T.
    Terashima, M.
    Nakano, Y.
    Hasegawa, Y.
    Tsukuda, H.
    Matsui, K.
    Masuda, N.
    Fukuoka, M.
    ANNALS OF ONCOLOGY, 2018, 29
  • [18] Malignant pleural effusion as a predictor of the efficacy of anti-PD-1 antibody in patients with non-small cell lung cancer
    Shibaki, Ryota
    Murakami, Shuji
    Shinno, Yuki
    Matsumoto, Yuji
    Goto, Yasushi
    Kanda, Shintaro
    Horinouchi, Hidehito
    Fujiwara, Yutaka
    Motoi, Noriko
    Yamamoto, Noboru
    Ohe, Yuichiro
    THORACIC CANCER, 2019, 10 (04) : 815 - 822
  • [19] Predictive biomarker of response to anti-PD-1 treatment in non-small cell lung cancer patients.
    Zheng, Xuan
    Hu, Yi
    Ma, Junxun
    Zhang, Fan
    Sun, Danyang
    Li, Lingling
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)
  • [20] Predictive biomarkers of response to anti-PD-1 treatment in non-small cell lung cancer patients.
    Zheng, Xuan
    Hu, Yi
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345